651
ROSNILIMAB, A PD-1 AGONIST ANTIBODY IN CLINICAL DEVELOPMENT FOR ULCERATIVE COLITIS, REDUCES PATHOGENIC PD-1+ T CELLS AND INFLAMMATORY CYTOKINE SECRETION IN PATIENT SAMPLES AND IN A MOUSE MODEL OF COLITIS
Date
May 5, 2025
Explore related products in the following collection:
